The application of in vitro model systems to evaluate the toxicity of xenobiotics has significantly enhanced our understanding of drug-and chemical-induced target toxicity. From a scientific perspective, there are several reasons for the popularity of in vitro model systems. From the public perspective, in vitro model systems enjoy increasing popularity because their application may allow a reduction in the number of live animals employed in toxicity testing. In this review, we present an overview of the use of in vitro model systems to investigate target organ toxicity of drugs and chemicals, and provide selective examples of these model systems to better understand cutaneous and ocular toxicity and the role of drug metabolism in the hepatotoxicity of selected agents. We conclude by examining the value and use of in vitro model systems in industrial development of new pharmaceutical agents.
INTRODUCTION
Because hundreds of compounds are synthesized each year, the cost of animal testing, which may exceed several million dollars to test a single substance 63 0362-1642/98/0415-0063$08.00 for safety assessment, needs to be reduced. The development of in vitro model systems to evaluate the toxicity of chemicals and drugs has thus become increasingly important. These in vitro systems may also enhance our understanding of the mechanisms of drug-and chemical-induced toxicity, because in vivo models are complicated by the presence of structural and functional heterogeneity and do not allow for mechanisms to be clearly defined or reproducibly examined. In vitro model systems enjoy increasing popularity from the public because their application in toxicity testing may allow a decrease in potential pain and suffering that animals may experience and a reduction in the number of animals utilized in biological testing.
Before in vitro findings may be related to in vivo human toxicity, certain basic steps should be followed when using in vitro cellular systems (see Table 1 ). The described protocol emphasizes the need to use human tissue or an animal tissue that responds to the human condition with fidelity. Of course, if it is known that a compound is selectively toxic to a particular organ, then one should try to use that tissue in an in vitro environment. The in vitro system should be developed and characterized so that it retains key functions and characteristics of the in vivo tissue and demonstrates when those characteristics are lost in vitro.
The use of model compounds, which are known to be toxic (positive controls) or nontoxic (negative controls) in vivo, is done initially to confirm that the in vitro system responds as the in vivo tissue would. Studies should be conducted with concentrations and times of exposure similar to the in vivo situation so that dose-and time-response effects can be demonstrated in the in vitro setting. By using a battery of cytotoxic parameters and measurements of cellular function, general cytotoxic characteristics of the compounds can be determined, followed by more detailed and sensitive evaluations of mechanisms of toxicity.
After a thorough examination of the model compounds to demonstrate the validity and sensitivity of the in vitro system to detect known toxic compounds, Table 1 An in vitro approach to investigate the toxicity of xenobiotics
Step 1. Identify the appropriate target organ and species
Step 2. Develop and characterize a suitable in vitro system
Step 3. With model test compounds (positive and negative controls) and reasonable in vitro concentrations and exposure times, perform toxicity studies Step 4. Employ a battery of cytotoxic assays to evaluate the compounds Step 5. After evaluation of the model compounds, measure the toxicity of unknown or previously untested agents Step 6. Compare and contrast their toxicity with the model compounds
Step 7. Examine mechanisms of toxicity with more detailed and in-depth investigations Step 8. Conduct interlaboratory validation studies unknown or untested compounds can be evaluated with the in vitro model system. The known toxicants can be compared and contrasted with the toxicity of the unknown agents. By conducting in-depth studies during early times of exposure before gross or overt toxicity is observed, one may obtain a better understanding of cellular mechanisms that lead to cytotoxicity or cell injury. Finally, collaboration with other investigators who use the same methodology and in vitro model systems as the original experiments will allow one to validate the use of the in vitro model system, as well as the parameters of toxicity used in the study.
In the following sections of this review, selected in vitro model systems are explored in detail to provide the reader with prototypic in vitro models that illustrate the principles of in vitro toxicology described above. These model systems include ocular and skin prototypes, which have been promoted as potential alternatives to the Draize test. Advantages and limitations of these systems are fully discussed. Hepatic systems are described as in vitro models to investigate mechanisms of hepatotoxicity of selected agents and to serve as applied research tools in the development of new drugs in the pharmaceutical industry.
MODEL SYSTEMS FOR CUTANEOUS AND OCULAR IN VITRO TOXICITY TESTING

Introduction
OVERVIEW Few whole-animal models used in the pharmaceutical, cosmetic/ personal hygiene, or chemical industry have stirred more debate among scientists and antivivisectionists than the now more than 53-year-old Draize models (1) for cutaneous and ocular toxicity testing. Likewise, few whole-animal models used in these industrial applications have generated as much necessary, informative, and descriptive data as the Draize models. Nonetheless, recent improvements in the isolation and culture of epidermal keratinocytes and corneal epithelial (CE) cells have made a tremendous contribution to cutaneous and ocular toxicity testing in terms of reducing the numbers of animals used and improving the understanding of molecular and cellular effects of potential irritants to the skin and eye. This expansion of research into potential alternative cutaneous and ocular toxicity model systems has been fueled by several disadvantages of the Draize tests.
DEFICIENCIES OF THE DRAIZE SKIN AND EYE TESTS Among the deficiencies of the Draize tests are the inability to obtain important information concerning potential mechanisms of toxicity of test chemicals, inadequate objectivity in obtaining irritancy scores, insufficient relevance of test chemical application to accidental exposure of human skin or eyes, inflated expenditures related to the large numbers of animals required and time-consuming evaluation, irreproducibility of results, and increased public desire to minimize whole-animal testing and any potential pain or suffering animals must endure (2, 3) . In vitro reconstruction of the numerous potential physiological parameters that may affect in vivo skin or eye response to irritants is clearly a daunting task that may not be entirely possible. Yet improved in vitro models may allow large-scale screening of thousands of test compounds (especially relevant with the increased use of combinatorial chemistry to synthesize potential profitable chemicals) and narrowing of the chemical search to promising compounds that may then be tested in whole-animal models. In that regard, the focus of this section is on promising supplemental and/or alternative in vitro models to the Draize tests.
Epidermal Keratinocyte Culture Models
Several transformed keratinocyte culture models (cell lines) have been used to study carcinogenesis, differentiation, apoptosis, and cell cycle regulation (4) , but the focus here is on normal (nontransformed) keratinocyte culture models because cutaneous toxicity testing of new drugs, cosmetic products, and other chemicals requires phenotypically normal cell systems (5) . Because the loss of differentiated function of transformed cell types undoubtedly confounds interpretation of the results (6), some evidence suggests that better correlation of in vitro toxicity testing with irritation potential in vivo may be obtained by using normal keratinocyte culture models as opposed to transformed cell lines (7) . In addition, a large variety of in vitro systems are used for cutaneous toxicity testing ranging from submerged keratinocyte and liquid-air interface skin cultures to three-dimensional reconstructed skin models (8) . However, focus here is on submerged monolayer epidermal keratinocyte culture models. The primary reason for this focus is a key concept in support of incorporating keratinocyte culture models into a battery of cutaneous toxicity tests. That is, keratinocytes make up the bulk (greater than 90%) of epidermal tissue mass (9, 10) , and viable keratinocytes (not exposed directly to air) participate in the conversion of environmental stimuli into biological signals that activate the inflammatory and hyperproliferative responses of the skin (11) . As such, submerged cultures of epidermal keratinocytes provide a model of a major component of the target epidermal tissue for assessing the effects of drugs or chemicals on the skin.
MODEL ASSUMPTIONS Some critical assumptions must be considered prior to accurate interpretation of in vitro results. First, exposure of keratinocytes to the test chemical assumes that adequate percutaneous absorption takes place in vivo and that the concentrations used in vitro simulate those that might be present at the basal keratinocyte level in vivo. Second, exposure of keratinocytes to the test chemical assumes that metabolites of the test chemical will be formed in vitro in an analogous fashion, as may occur in vivo. Third, interpretation of results with keratinocyte cultures is limited to assuming a lack of involvement of other cell types that would be present in vivo, such as fibroblasts, melanocytes, and Langerhans cells. Fourth, testing for powders, gels, creams, other complex topical formulations, and insoluble material is inherently difficult, if not impossible, in cell culture models (12) . Finally, any or all of these assumptions may be more or less important when assessing the in vitro toxicity of specific chemical or therapeutic classes of compounds; that is, the physicochemical properties of individual test compounds (13) and the relationship of in vitro exposure to the anticipated human skin exposure cannot be overlooked.
CELL CULTURE METHODS Isolation, primary culture, and subculture of basal epidermal keratinocytes from a variety of species follow similar protocols (2, 14, 15) . Common sources of epidermal tissue for primary keratinocyte culture are newborn and adult human skin (obtained from circumcision, biopsy, and other surgical procedures), newborn and adult rats, and mice. However, the desire to eliminate confounding species-specific responses of keratinocytes and availability of human cells from commercial vendors has likely decreased the use of rats and mice as primary tissue donors.
BIOLOGICAL ASPECTS OF KERATINOCYTE CULTURES THAT MAY INFLUENCE
TOXICITY TESTING Several major factors for optimal keratinocyte growth must be considered prior to implementation of the culture model into cutaneous toxicity testing. First, plating density dramatically influences clonal growth of keratinocytes. For example, low plating densities often result in poor keratinocyte growth, presumably because of deficient autocrine or paracrine release of growth factors from the keratinocytes themselves (16) . Optimal growth is typically observed when moderate (approximately 5,000-10,000 cells per cm 2 ) plating densities are utilized (16, 17) . In contrast, higher plating densities may accelerate terminal differentiation of the keratinocytes and thus confound cutaneous toxicity testing as described below. Therefore, initial plating density may influence toxicity testing in epidermal keratinocyte cultures.
Second, culture media and supplements may have profound effects on keratinocyte growth in vitro. Epidermal keratinocytes are routinely cultured in a growth media consisting of serum-free MCDB 153 (presumably an abbreviation for Molecular Cellular and Developmental Biology, the department in which the media was characterized) with supplements, including epidermal growth factor, insulin, ethanolamine, phosphoethanolamine, and bovine pituitary extract (BPE) (18) . Frequently, high amino acid supplementation is used to increase growth media concentrations of histidine, isoleucine, methionine, phenylalanine, tryptophan, and tyrosine (17) . Although it lacks serum, this growth media is only semi-defined in content because BPE is used and bovine serum albumin (BSA) is added, which, depending upon the source and purity, may have variable amounts of contaminating fatty acids, bile acids, and keto acids (16) . Like other target organ cell culture models that use serum-supplemented media (e.g. hepatocytes), growth characteristics of keratinocytes in culture may change as a result of lot-to-lot variability in BPE or BSA. Hopefully, the use of BPE in keratinocyte growth media will eventually be replaced, because it is now known that one of the major components of BPE that stimulates keratinocyte growth is prolactin (14) . Furthermore, the use of ill-defined supplements may further complicate culture of keratinocytes because of variable amounts of calcium that may accompany specific lots of BPE or BSA. Calcium clearly plays an integral role in keratinocyte differentiation; consequently, optimal concentrations of calcium have been identified where low concentrations (0.1 to 0.3 mM) provide optimal clonal growth of basal keratinocytes and minimize proliferation of contaminating fibroblasts, and where normal concentrations (1.0 to 2.0 mM) stimulate terminal differentiation (17, 18) . Because terminal differentiation is at least partly dependent upon extracellular calcium concentrations and differentiation may affect results of toxicity testing in keratinocyte cultures, optimal calcium concentrations must be controlled when epidermal keratinocyte cultures are used for toxicity testing.
Third, evidence indicates that the common growth media used for keratinocyte culture do not provide all the nutrients necessary for normal clonal growth of keratinocytes in vitro. While adult human keratinocytes typically grow well to the fifth or sixth passage (subculture), essential fatty acid deficiency occurs in the cultures as early as the first passage; this is indicated by decreased amounts of diet-derived polyunsaturated fatty acids (19) . Essential fatty acid deficiency can be corrected in keratinocyte cultures, but interestingly, correction is not obtained by supplement of essential fatty acids alone and requires supplementation of nonessential palmitic acid (19) . While this deficiency may contribute to rapid growth and maintenance of a relatively undifferentiated state of keratinocytes, it may also directly affect in vitro toxicity studies, particularly when the endpoints evaluated are releases of inflammatory mediators such as arachidonic acid (19) , but also when other endpoints are utilized. For example, essential fatty acid-deficient keratinocyte cultures survived high concentrations of tert-butyl hydroperoxide (tBHP, an oxidative stress-inducing agent that produces lipid peroxidation); yet when serum-free keratinocyte growth media was supplemented with linoleic acid, lipid peroxidation and keratinocyte death ensued after exposure to tBHP (20) .
Finally, the relative state of differentiation must be considered for the use of epidermal keratinocyte cultures in cutaneous toxicity testing. Keratinocyte differentiation is a physiological necessity in vivo whose main function is the protection of the outer body, which is accomplished through transforming relatively undifferentiated, proliferative keratinocyte stem cells into nonproliferative, dead corneocytes and providing a rigid, stratified structural barrier (10) . With the acquisition of a battery of antibodies directed against various protein markers of differentiation (basonuclin, filaggrin, integrins, involucrin, keratins, etc), it is now possible to identify specific stages of differentiation among keratinocyte populations in vitro (10, 17, (21) (22) (23) (24) . With these tools in hand, several known factors that stimulate keratinocyte differentiation have been identified and include high calcium concentrations (10, 11, 18) , vitamin D (10), hydrocortisone (10), epidermal growth factor (10), and transforming growth factor α (10). Similarly, several known factors that simulate keratinocyte proliferation and clonal growth have been identified and include low calcium concentrations (10, 17, 18) , retinoids (10), cholera toxin (10), and adrenergic agents (10) . A prime example of the influence of the relative state of differentiation affecting the results of toxicity tests involves toxicants that may induce oxidative stress and lipid peroxidation in the mechanisms of toxicity. Differentiation of keratinocytes in vitro resulted in a calcium-specific increase in cellular antioxidant defenses, culminating in tolerance to high concentrations of cumene hydroperoxide (25) , another oxidative stress-inducing agent.
VALIDATION OF IN VITRO STUDIES: CORRELATION OF IN VITRO RESULTS WITH IN
VIVO DATA Many reports have addressed the issue of validation of epidermal keratinocyte cultures as models for dermal irritancy testing; therefore, this brief overview is not intended to be inclusive. Advantages of keratinocyte culture models aside, the key question is whether cutaneous toxicity testing conducted in vitro corresponds with results obtained in vivo (5, 26) . More specifically, the question is whether the in vitro toxicity data correspond with human toxicity data, because the test systems are obviously being developed to predict human response (7, 27) . Several different concerted laboratory efforts and their resulting studies have directly addressed this question. Most of these studies have evaluated surfactants as model compounds largely because the surfactants are well-known skin irritants widely used in cosmetic and pharmaceutical formulations and household cleaning products (2, 28) .
Using normal human epidermal keratinocytes (NHEK) obtained from newborn foreskin, Korting and colleagues measured cytotoxicity as the end point in NHEK cultures exposed to a variety of anionic, amphoteric, and nonionic surfactants (27) . Two standard cytotoxicity tests were used: neutral red release (NRR), where neutral red-loaded viable cells were subsequently incubated with surfactants, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction, where viable cells reduce MTT (27) . In addition, in vitro toxicity data were compared to human skin irritancy data, which included transepidermal water loss, colorimetry, and visual scores obtained from humans exposed to the surfactants (27) . The investigators found a good correlation between the effective doses of surfactants that produced a 50% decrease in MTT reduction (ED 50 ) and the in vivo irritancy data (r = 0.91) from six of the surfactants tested. Noteworthy is the fact that NHEK cultures from newborn skin exposed to surfactants and cationic detergents exhibited a good correlation (r 2 = 0.833) between MTT toxicity data and in vivo rabbit skin irritation (29) , indicating that in vitro results may be predictive of the Draize skin irritation potential as well as the more important human skin irritation potential.
Using NHEK cultures exposed to sodium dodecyl sulfate (SDS), polyoxyethylene 20 sorbitane monolaurate (Tween 20), and octylphenoxypolyethoxy ethanol (Triton X-100), Shivji and colleagues measured cytotoxicity (crystal violet staining), tritiated arachidonic acid ( 3 H-AA) release, and interleukin-1α (IL-1α) mRNA content (30) . The toxicity rankings of the surfactants by cytotoxicity and 3 H-AA release corresponded with their rankings by in vivo irritation potential (30) . Although IL-1α mRNA did increase with surfactant exposure, increased IL-1α mRNA content did not correspond with in vivo irritancy rankings (30) . Because keratinocytes constitutively express IL-1α and store and release this inflammatory mediator upon exposure to irritants, measurement of IL-1α release may be a valuable test in a battery of in vitro assays to assess relative irritancy potential, as long as the protein maintains stability in the presence of test compounds (30) . Currently, in vitro toxicity testing in keratinocyte cultures should include a battery of assays, because a single indicator that perfectly correlates with in vivo irritancy potential has yet to be identified. Advantages and disadvantages of some of the standard in vitro cytotoxicity assays have been reviewed previously (31) . Cytotoxicity assays and measurements of release of inflammatory mediators should at least be incorporated into this battery of assays.
SUMMARY Use of epidermal keratinocyte cultures appears to be an important in vitro model that can provide valuable information concerning potential mechanisms of toxicity of test compounds and reduce the numbers of animals required for Draize skin testing. Whether keratinocyte culture models can completely replace Draize skin testing is contingent upon further validation of the models using a host of other known human skin irritants. Future investigations into replacement models for the Draize skin test should focus on validation and perhaps should also incorporate coculture models to assess the important role of intercellular communication in skin irritation.
Corneal Epithelial Cell Culture Models
MODEL ASSUMPTIONS Critical assumptions accompanying the use of corneal epithelial (CE) cell culture models for ocular toxicity testing include many of the assumptions made with epidermal keratinocyte culture models; however, adequate absorption of the test compound across the corneal epithelium may be of much less importance than in the case of basal epidermal keratinocytes and percutaneous absorption because the corneal epithelium will be in direct contact with the potential irritant both in vitro and in vivo. In addition, the corneal epithelium does not have the thick protective barrier of keratinized or cornified cells as is present in the skin. Finally, CE cell cultures lack the intrinsic clearing mechanisms (tearing and blinking) that are present in vivo; as a result, contact with test compound is continuous in vitro, which may contribute to generation of false positive tests for potential ocular irritants. As with any target organ cell culture model, interpretation of results rests entirely upon the critical assumptions taken with each in vitro model (32) (33) (34) .
CELL CULTURE METHODS Perhaps as an extension to the many years of utilizing rabbits for ocular toxicity testing with the Draize model and the ability to efficiently obtain large amounts of viable corneal epithelium, rabbits are the common tissue source used for isolation and culture of CE cells. However, in contrast to keratinocytes, human donors for viable corneal tissue are not readily available, and human donors will not likely replace animal CE donor tissue. At first glance, this would appear to be a major disadvantage of the rabbit CE cell culture model. However, even though the rabbit eye may be more sensitive to toxic insult in vivo, the biochemistry and gross morphological organization of rabbit corneal tissue seems to be representative of most mammals (35) .
The CE cell isolation and culture procedure was initially described in 1982 (36) and has since undergone slight modifications (32) . The first step in isolation and culture of CE cells is surgical excision of adult rabbit corneas. The endothelial layer is removed and the epithelium is separated from the stroma by dispase digest and gentle scraping. Following trypsinization of the epithelial layer, cells are washed with complete growth media consisting of Dulbecco's modified Eagle's medium supplemented with high glucose, fetal calf serum, insulin, transferrin, selenium, putrescine, progesterone, and hydrocortisone. CE cells grow to confluency in three to four days in a humidified, 5% carbon dioxide incubator kept at 37
• C (32). This procedure typically yields a homogeneous population of CE cells with very few contaminating cell types.
BIOLOGICAL ASPECTS OF CE CELL CULTURES THAT MAY INFLUENCE TOXICITY
TESTING Several major biological aspects of CE cell growth must be considered prior to implementation of the culture model into ocular toxicity testing. First, normal repair mechanisms of corneal epithelium are intact in vitro (37), and these mechanisms may have dramatic influence on in vitro ocular toxicity testing. That is, depending upon the endpoint assessed and whether these endpoints are dependent upon an intact monolayer, results of toxicity testing may be influenced by innate regrowth and repair mechanisms following toxic insult (34) . Thus, when temporal relationships of the test compound are completely unknown, partial toxicity and subsequent loss of contact inhibition may allow migration and regrowth of remaining viable CE cells, thereby masking any response from the test compound (34) . Similarly, release of plasminogen activator following toxic insult may allow temporary detachment for ensuing migration of viable CE cells (34) , and if the endpoint measurement coincides with detachment, misinterpretation of results is likely.
Second, enzyme profiles of CE cell cultures vary significantly with respect to time in culture and also differ significantly from other cell types. For example, Grant and colleagues (32) found that lactate dehydrogenase (LDH) activity decreased 40%, while aldolase activity increased 140% between days one and three in culture, but following these changes, enzyme activity remained stable through day eight in culture. Similarly, glucose 6-phosphate dehydrogenase (G6PHD) activity decreased 26% on day one in culture, remained stable betwen days one and six, and further decreased 52% by day eight in culture. In addition, the total LDH activity of CE cell cultures was approximately 10 times higher than that of cardiomyocyte cultures (32) . Taken together, these results exemplify the importance of biological aspects of CE cell cultures that may have dramatic effects on toxicity testing, particularly if the endpoints evaluated include measurement of cytosolic enzyme leakage (e.g. LDH). As with keratinocyte cultures, in vitro toxicity testing in CE cell cultures should include a battery of assays that include perhaps the NRR or NR retention and MTT assays to account for the altered enzyme profiles (32) .
Third, adequate understanding of growth regulation of rabbit CE cells in vitro is lacking. Some of the major growth stimulators of other cell types such as insulin, epidermal growth factor, and serum appear to induce CE cell growth in vitro (37) . Interestingly, in addition to stimulating epidermal keratinocyte growth (10), cholera toxin increases the ability of cultured CE cells to adhere to plastic and collagenous substrates and is required for optimal growth through a mechanism that involves increased cyclic adenosine monophosphate (cAMP) and increased synthesis and secretion of cell surface glycoproteins (37) . Test compounds that may interfere with cAMP levels may, therefore, alter results of in vitro toxicity testing through altering growth and/or migration of CE cells. This characteristic provides a particular advantage when using CE wound closure in culture as an in vitro model of ocular irritancy (38) . In addition, adrenergic receptors are present on the surface of CE cells grown in culture, as they are in vivo, and the cells respond to β-adrenergic stimuli with an increase in cAMP synthesis (37) . However, cultured CE cells lack the serotonergic pathway found in adult rabbit in vivo (38) . These characteristics of CE cell cultures must be taken into consideration for in vitro toxicity testing, particularly when one of the pathways may be suspect in the mechanism of toxicity of the test compound.
Finally, as with most primary cell culture models, initial enzymatic and mechanical dissociation of corneal tissue for cell isolation presents stressful stimuli that may produce a variety of responses from the cell. Excision of BALB/c mouse corneal tissue induced rapid synthesis of IL-1α, with peak protein accumulation occurring at 6 h after excision (39) . Interleukin-6 (IL-6) was also induced with mechanical trauma, but peak protein accumulation occurred at 18 h (39). Interestingly, the data strongly suggested that mechanical trauma induced IL-1α, which subsequently induced the synthesis of IL-6, but trauma did not induce IL-1β or tumor necrosis factor α synthesis (39) . Because measurement of release of inflammatory mediators has been demonstrated to be a good endpoint for in vitro toxicity testing with epidermal keratinocyte cultures, the assays may also be attractive endpoints in CE cell cultures. Therefore, consideration of the traumatic effect of cell isolation on release of inflammatory mediators is important when utilizing CE cell cultures for ocular toxicity testing. Further studies are required to determine temporal cytokine or inflammatory mediator profiles throughout the CE cell culture period and whether the effects of mechanical trauma differ with respect to rabbit corneal tissue.
VALIDATION OF IN VITRO STUDIES: CORRELATION OF IN VITRO RESULTS WITH IN
VIVO DATA Numerous studies have addressed the issue of validation of CE cell cultures as models for ocular irritancy testing, and this brief overview is not intended to be inclusive. Rather, focus is on a few of the reports that have provided strong evidence for validation of the model. As with the epidermal keratinocyte cultures, focus here is on studies evaluating cytotoxic potential of surfactants because of their importance in cosmetic, pharmaceutical, and household cleaning preparations. With the relative lack of informative data of human eye exposure to surfactants, most of the validation studies have attempted to correlate in vitro toxicity tests in CE cell cultures with in vivo Draize eye irritancy potential of the compounds. Therefore, despite the obvious need to compare in vitro toxicity with human irritancy potential, little information exists, largely because of the ethical difficulty in designing such studies.
Using primary CE cell cultures, Grant and colleagues tested eight surfactants in a variety of cytotoxicity assays, including LDH leakage, MTT reduction, and NR retention (32) . Cytotoxicity (using all three viability assays) of different types of surfactants were ranked, and cationic surfactants exhibited a greater cytotoxic potential than anionic and amphoteric surfactants, the latter two exhibiting a greater cytotoxic potential than nonionic surfactants. Although nonionic, Triton X-100 has a cytotoxic potential roughly equivalent to the anionic surfactants and is also a severe irritant in vivo. Importantly, the in vitro rankings corresponded well to reported in vivo Draize rabbit eye test data (32) . For example, the MTT reduction assay gave better correlation results for one particular surfactant, and the LDH leakage assay underestimated cytotoxicity when only 1-h initial leakage was determined for some surfactants: a phenomenon that further exemplifies the importance of temporal relationships in the in vitro cytotoxicity assays (32) .
In a subsequent investigation by Grant & Acosta, examination of delayed toxicity of surfactants in CE cell cultures was conducted (31) . Results indicated that benzalkonium chloride (BzCl, a cationic surfactant) produced initial injury followed by greatly increased delayed toxicity in vitro, corresponding to in vivo results in which initial injury induced by BzCl is followed by sustained tissue damage with very little reversibility. In contrast, sodium dodecyl sulfate (SDS, an anionic surfactant) produced the greatest cytotoxicity during cell contact, and there were only small increases in cell injury after removal of the surfactant. Again, this corresponded to in vivo injury produced by SDS when there were signs of reversibility of the initial injury (31) . As an important side note, more mechanistic information of BzCl-and SDS-induced toxicity was later obtained using CE cell cultures, further exemplifying the advantages of the model (34) . For example, BzCl was found to produce sustained increases in intracellular free calcium concentrations, decreases in intracellular pH, and decreases in adenosine triphosphate (ATP)/adenosine diphosphate (ADP) ratios. In contrast, SDS was found to produce decreases in intracellular free calcium concentrations and altered intracellular pH (34) .
In one of the few studies attempting to evaluate mixtures of surfactants, Yang & Acosta tested two groups of surfactants, each with the same components in varying proportions, in CE cultures by measuring cytotoxicity with the LDH leakage and MTT reduction assays (40) . Surfactant mixtures of various concentrations of lauroamphocarboxyglycinate (HMS) and SDS in the first group (five different mixtures) and HMS, SDS, and polysorbate 20 (Tween 20) in the second group (five different mixtures) were prepared in proportions such that the total surfactant concentration was unchanged within each group and equal between each of the two groups. In vivo Draize scores were compared directly to in vitro EC 50 values calculated from the viability assays. Good correlation was found between cytotoxicity in vitro and the reported Draize eye scores within each group of surfactant mixtures studied. Of the ten different mixtures tested, only one in the second group failed to provide good correlation (40) . SUMMARY Together, these investigations provide good correlation of in vitro toxicity of surfactants with in vivo Draize eye scores, good correlation of delayed toxicity in vitro with in vivo observations, and preliminary delineation of possible different mechanisms of toxicity for two chemically-related surfactants. Finally, Draize eye testing of single test compounds mandates the use of large numbers of rabbits. Thus, it stands to reason that testing complex mixtures of surfactants (a manner in which they are likely to be used) then dramatically increases the magnitude of the study when all possible combinations require testing. Cultures of CE cells provide a good model to test different mixtures of surfactants, certainly allowing selection of the most or least likely irritating combinations prior to in vivo testing. As with keratinocyte culture models, whether CE cell cultures can completely replace Draize eye testing is contingent upon further validation of the model using a host of other known human ocular irritants. Future investigations into replacement models for the Draize eye test should focus on validation and expanding the knowledge base of biological aspects of CE cells that may influence in vitro toxicity testing and correlation with in vivo data.
IN VITRO HEPATIC SYSTEMS FOR MECHANISTIC TOXICOLOGY AND DRUG METABOLISM STUDIES
Introduction
OVERVIEW Over the past decade, use of in vitro method/models has expanded greatly to reduce traditional animal testing models when appropriate. There are many hepatic in vitro test systems where one must consider the advantages and disadvantages of each model system for their specific research objective. The "levels" of integration of these hepatic in vitro model systems include (a) isolated perfused organs; (b) tissue slices; (c) cell culture/suspensions; (d ) isolated organelles, membranes, or enzymes; (e) invertebrates; ( f ) non-living systems; and (g) computer models (41) . These in vitro test systems are popular because they have a high level of integration to study interactions of chemicals with intact cells, they are likely to be within the expertise of most tissue culture laboratories, and they will allow for species comparisons. However, they cannot replicate the complex interactions of the entire animal in vivo. Thus, in vitro tests usually complement in vivo animal testing and may allow for significant reductions in the number of animals needed (41) .
These various hepatic in vitro systems can allow one to determine the mechanism of hepatotoxicity, such as cytoskeleton alterations, disruption of Ca 2+ homeostasis, disruption of tissue repair mechanisms, inhibition of cellular energy, inhibition of transport, loss of cell volume homeostasis, and metabolic activation and covalent binding. Moreover, there are endpoints that can be measured-such as albumin synthesis and secretion; ATP, ADP, and AMP content; cholesterol and lipoproteins synthesis; conjugated bile acids and bilirubin transport; cytochrome P450 (CYP) levels and activities; DNA and protein synthesis; gluconeogenesis; glutathione levels; intracellular K + and Ca
2+
; liverderived serum enzymes (alkaline phosphatase, aspartate and alanine aminotransferase); membrane leakage of cytosolic enzymes; morphologic changes; metabolic conversion of dyes such as MTT; and ureagenesis (41) .
Traditionally, hepatocyte systems have been commonly used in vitro models for studying hepatic function and toxicity. Monolayer cell cultures have been widely used in several scientific disciplines to study different aspects of liver function and to predict hepatotoxicity. Reasons for the popularity include ethical and economic considerations, increased knowledge about the technical aspects of hepatocyte isolation and culture, relative ease of obtaining a homogeneous cell preparation, and the high drug-metabolizing capacities of hepatocytes (42) . Recently, the use of precision-cut liver slices for evaluating both toxicity and drug metabolism has increased. Human liver slices are used to identify human-specific chemical metabolites, to study potential drug-drug interactions, and to evaluate the toxicity potential of new product prototypes at the earliest stages of pharmaceutical development (41) . Moreover, commercial sources of fresh cold-preserved human liver slices are available from human livers that could not be used for transplantation (41) . Hepatocytes have high biotransformation activity that may result in the formation of reactive species. These reactive species can cause DNA damage and thus may aid in the investigation of chemical-induced genotoxicity (42) . Many hepatic in vitro models are used in mechanistic toxicology; however, emphasis here is on the use of cell culture models.
There are several basic steps that should be considered before utilizing in vitro cell culture systems for toxicity investigations of compounds-such as (a) the identification of target organ in which toxicity occurs; (b) the use of human tissue or tissue from a species of animal that responds to the toxic insult; (c) optimum cell culture conditions to maximize cell growth, differentiated characteristics, and retention of specialized functions; and (d) characterization of the cell culture system's key functions (43) . After the cell culture procedure is established, the next consideration is the design and interpretation of any in vitro experiments to be performed. Several cytotoxic indices should be used to obtain a thorough understanding of toxicity. Also, it is necessary that known hepatotoxicants are selected as positive controls to confirm that the cell culture system responds as the in vivo tissue. Lastly, the time of exposure and concentrations of compounds should be similar to what would occur in vivo. At this point, the cell culture system can be used to investigate unknown compounds for cytotoxicity and mechanistic studies. Mechanistic studies can be performed during early time periods prior to toxicity to identify mechanism of cellular damage. The validity of the cell culture system and indices of toxicity used in the study should be verified by an interlaboratory study that utilizes the same methodology and collaborates the findings of the original experiments (43).
CELL CULTURE MODELS For hepatotoxicity testing, an in vitro system is needed that expresses specific liver functions observed in vivo. Therefore, shortterm culture systems (i.e. exposure period less than 24 h) appear to be most suitable for such studies (42) . Long-term cultures of hepatocytes may be used for induction in various species (44) (45) (46) and some inhibition studies in which positive controls such as phenobarbital, β-naphthoflavone, pregnenolone 16α-carbonitrile, isopropanol, rifampicin, and clofibrate should be included. The promising long-term models seem to be cocultures of hepatocytes (47), either with rat liver epithelial cells of primitive biliary cell origin or with certain other cell lines (48) , and three-dimensional hepatocyte cultures.
The two-step collagenase perfusion method is recommended for the preparation of hepatocytes from livers of various species (49) . These livers are typically perfused with calcium-free buffered solutions that sometimes include calciumchelating agents, followed by perfusion with a collagenase solution.
Because CYP is known to be a necessary catalytic component of the liver in metabolism of many xenobiotics, primary cultures of rat hepatocytes have been advocated as experimental systems to study the metabolic activation and toxicity of various compounds. Despite the historically noted decline of CYP in cultured liver cells (50, 51) , it has been demonstrated that primary cultures of postnatal rat hepatocytes can be maintained in culture for as long as 25 days, with no apparent changes in morphology or liver-specific differentiated functions characteristic of normal parenchymal cells in vivo, by supplementation of the culture medium with essential components such as insulin and hydrocortisone (52) (53) (54) (55) . Furthermore, flavin-containing monooxygenase (FMO) has been demonstrated in the in vitro model of cultured postnatal rat hepatocytes (56, 57) , adult rat hepatocytes (58) , and mouse astrocytes (59) . Thus, the cell culture system's enzymes (CYP and FMO) should be sufficient to perform mechanistic studies of drug-induced hepatotoxicity. Our research laboratory has utilized primary culture systems of rat hepatocytes to investigate the mechanism of toxicity of many drugs (53, (55) (56) (57) (60) (61) (62) (63) (64) (65) . Recently, we used this system to evaluate N-deacetyl ketoconazole's cytotoxicity and the role of FMO in its potential bioactivation to reactive metabolites. In addition to the various cytotoxic end points evaluated such as LDH and MTT, we were able to evaluate the role of FMO within the hepatocyte culture. Cotreatment with methimazole, a competitive substrate for FMO, produced a significant decrease in the percentage of LDH leakage as early as 0.5 h, when compared to cells treated solely with N-deacetyl ketoconazole. Also, the toxicity was significantly enhanced as early as 0.5 h by n-octylamine, a known positive effector for FMO (57) . These results demonstrate that N-deacetyl ketoconazole is a more potent cytotoxicant than ketoconazole, as reported previously by our laboratory; we expressed its toxicity in a dose-and time-dependent manner (64) . Furthermore, N-deacetyl ketoconazole's cytotoxicity was enhanced with n-octylamine and suppressed with methimazole, suggesting a role for FMO in the toxicity of the metabolite (57).
ADVANTAGES AND DISADVANTAGES Characteristically, in vitro methods are usually easy to set up, inexpensive, and simple to run and automate; yield quick results; and permit replication and good quantification. In vitro methods are used to answer questions at the cellular or molecular level, whereas whole animals are used to answer questions at the organ and interorgan level (66) . Primary cultures of rat hepatocytes offer several potential advantages over whole animals when used as models for drug biotransformation and detection of toxic chemicals, and for evaluating their cellular mechanism of toxicity. There are several advantages of cell culture models: (a) morphological observations of individual cells can be seen under the microscope; (b) blood flow, heterogeneity of cell type, and nervous and humoral factors are eliminated; (c) nutritional and hormonal status, oxygen supply and concentration, and time exposure to test compounds are better controlled; (d ) cells have time to recover from trauma sustained during the isolation procedure; (e) monolayer cultures can be maintained for long periods of time; and ( f ) monolayer cultures permit the study of the effects of toxicants on functions requiring organization of cells. Because of interspecies differences in metabolic pathways, nature of metabolites, and relative rates of biotransformations and because in some cases, in vivo studies in humans cannot be conducted for ethical reasons, it is essential that these data be obtained from in vitro human systems (45) . Therefore, a major advantage of in vitro methods is that human cells and tissues can be used, thereby eliminating the need for extrapolating data from laboratory animals to humans. Also, the results obtained from human tissue will have a direct relevance to human safety assessments of the drug. However, use of primary cultures of human cells involves a range of safety, legal, and logistical issues that need to be overcome if human tissues become widespread for research use (66) .
Some limitations of in vitro methods are the result of the direct extrapolation of in vitro data to the in vivo situation in both pharmacological and toxicological investigations. The limitations include (a) disruption of cellular structural integrity and intercellular relationships after dissociation of the tissue; (b) artifactual drug target (i.e. binding sites may be created which are not normally functional in vivo); (c) unknown therapeutic utility or advantage; (d) differences between in vitro and in vivo compound biokinetics; and (e) the difficulty in assessing the concentration at which the drug is pharmacologically and toxicologically active and relevant to in vivo dose levels. Thus, a researcher must consider the advantages and disadvantages of the in vitro systems utilized to answer their specific research objective.
In Vitro Hepatic Drug Metabolism and Toxicology Systems
In vivo animal studies have been traditionally used to investigate drug metabolism and the ability of chemicals to cause injury to the host organism. These physiological models are important for the demonstration that chemicals have an adverse effect on the liver. However, these in vivo models encounter several problems that limit their usefulness. Problems include the cost of maintaining experimental animals, the difficulty of isolating and separating pure metabolites from parent compounds in highly complex biological fluids, and inadequate quantities of metabolites isolated in vivo for physiochemical or biochemical analysis. An important application of in vitro systems is the preliminary screening of xenobiotics for potential pharmacological effects. The cell culture system provides an attractive model for elucidation of the mode of interaction between a compound and the cellular, subcellular, and molecular levels of the tissue. The mechanism of action of a compound can be studied under rigidly controlled conditions. In general, it is easier to monitor the biological effects of toxic chemicals in cultured cells by microscopic inspection and biochemical methods.
Knowledge of the metabolic pathway and metabolites of a drug is critical for the interpretation of the pharmacological and toxicological data. Thus, it is now accepted that hepatotoxic effects induced by administration of drugs or chemicals are very often not the result of the parent compound but of reactive metabolites formed inside the cell. These reactive metabolites and/or intermediates are often electrophilic and lead to irreversible alkylations of cellular macromolecules responsible for tissue damage. The formation of reactive intermediates from a compound can be suspected from covalent binding to subcellular components such as proteins or unsaturated fatty acids. Also, evidence can be obtained from in vivo and in vitro studies in which metabolic rates can be evaluated by pretreatment with known inducers and inhibitors of phase I metabolism.
IN VITRO HEPATIC MODELS There are many in vitro systems that employ animal and/or human cells derived from the liver and/or from extrahepatic tissues available for studying the metabolism of compounds. These systems include tissue slices, primary cell cultures, genetically engineered cell lines expressing specific xenobiotic-metabolizing enzymes, and microsomes and other subcellular fractions (66) . Many pharmaceutical companies have already begun to utilize some of these approaches (67, 68) . The use of in vitro systems derived from different species can provide a basis for qualitative and quantitative interspecies comparisons. Because the metabolism of a drug may involve several drug-metabolizing enzymes of both phase I and phase II, some of which are microsomal or cytosolic, cellular systems are more convenient. Freshly isolated human hepatocytes and primary cultures of these cells have been used for this purpose. Biotransformation enzymes are greater in centrilobular hepatocytes, whereas periportal hepatocytes have higher levels of glutathione and a greater capacity for bile acid uptake and secretion into the canaliculi. Blaauboer et al (42) have listed biotransformation criteria that are recommended for biotransformation studies. A few of these recommendations are as follows: (a) Biotransformation patterns should be determined using suspension incubations of freshly isolated hepatocytes; (b) the quality of the isolated hepatocytes and the reliability of the methodology being used for each new experiment should be reproducible between different hepatocyte preparations; and (c) studies should be undertaken to extend the list of available probe substrates, specific antibodies, cDNAs, and antisense RNA probes for the key hepatic enzymes involved in xenobiotic metabolism, such as CYP, FMO, glutathione-S-transferases and glucuronosyl transferases. These tools are important for quality control of hepatocyte culture systems and their validation.
Kling (67) provides a review of the industry's approach to evaluating drug metabolism. Eli Lilly & Co. researchers use in vitro techniques to identify possible drug-drug interactions by the antipsychotic agent olanzapine. Merck Research Laboratories predict in vivo effects using in vitro modeling. The use of liver microsome samples from rats, rhesus monkeys, and humans provide alternative ways for the evaluation of drug metabolism and toxicity studies. Pfizer applies a series of literature-based and in-house mathematical models based on data from its drug candidates over the past 10 years to determine the pharmacokinetic profile of a drug candidate, which includes the drug's half-life, its distribution, its interaction with other drugs, and its toxicity. Information gained by pharmaceutical companies can help predict whether a compound is likely to complete clinical trials and reach the market. Therefore, many researchers in the academic and industrial settings extensively utiltize in vitro hepatic systems to evaluate the metabolism of various drugs.
CELL CULTURE MODELS Primary cultures of human hepatocytes provide an invaluable model for in-depth investigation of drug metabolism. There are many research laboratories that utilize cell cultures for drug metabolism studies in conjunction with other in vitro assays. Important considerations for enzyme induction studies in cell culture include the following: (a) the use of collagencoated dishes in a serum-free, chemically and hormonally defined medium; (b) the role of confluent cultures for both the maintenance of the differentiated phenotype and CYP expression and induction; (c) the understanding that treatment with inducers should be started 48 h after plating, since cells do not apparently respond to inducers during the first 24-48 h; and (d) the use of appropriate concentrations for enzyme induction (45) . Some drugs, such as rifampicin (<10 µM), are potent inducers at low doses, while others, such as phenobarbital (>1 mM), require high doses. The use of human hepatocytes for the screening of inhibitors remains necessary to confirm that the effect observed in the cell-free system also occurs in hepatocytes, to detect inhibitors that result from sequential activation by several enzymes systems, and to detect a possible effect on enzyme accumulation (45) .
Cell culture conditions for inhibition studies require a substrate concentration in the extracellular medium that is below or similar to the K m for the enzyme.
The inhibitor concentration to be tested must cover a range for at least 10 times below to 10 times above the substrate concentration in the extracellular medium. In all cases, positive controls (known inhibitors) in experiments must be run in parallel with the test compound. When a drug is metabolized by more than one CYP or enzyme, these predictions become more difficult to make because the extent of the interaction will depend on the relative contribution of the target enzyme. Also, interactions occurring in vivo may not be predicted with in vitro methods because they do not originate from the metabolism of the drug but from other processes, including transport, tissue distribution, or excretion (45) .
In contrast to adult hepatocytes, fetal hepatocytes in vivo are growing cells. DNA synthesis, as measured by the rate of thymidine incorporation, is faster in rat fetal hepatocytes than in adult hepatocytes and is independent of serum or mitogens added to the cultures. DNA synthesis in fetal hepatocytes can also be stimulated, as in adult hepatocytes, by the addition of various polypeptide growth factors, including epidermal growth factor and hepatocyte growth factor (54) . Rat fetal hepatocytes have exhibited biotransformation pathways, including testosterone hydroxylation, ethoxycoumarin and ethoxyresorufin deethylation, and lauric acid hydroxylation. The biotransformation enzyme levels and activities are inducible by pretreatment of the cultures with dexamethasone, phenobarbital, and clofibrate. Both hepatocytes and slices derived from human fetuses contain a developed rough endoplasmic reticulum, short sections of smooth endoplasmic reticulum, matrix-rich mitochondria, free ribosomes, and a well-developed Golgi apparatus. As in adult human hepatocytes, treatment of fetal hepatocytes with the inflammatory mediator IL-6 produces an acutephase response exhibited by the induced expression of C-reactive protein and α 1 -antichymotrypsin. Fetal hepatocytes, like adult hepatocytes, exhibit a reduction of albumin synthesis in response to transforming growth factor β and have the functional capacity to form bile (54) .
Efforts to improve the quality of hepatocyte cultures for drug metabolism studies have been performed by altering cell culture medium composition (69), using extracellular matrices (70) (71) (72) , and utilizing cocultures (47, 48) to optimize culture conditions. Although hepatocyte cultures allow reproduction of in vivo pattern of biotransforamtion of xenobiotics, it must be realized that these cultures cannot be used to predict in vivo clearance of drugs.
TISSUE SLICES A liver slice consists of the various cell types of the organ where the cells maintain normal architecture, acinar localization, and cell-cell communications. The functional heterogeneity and biochemical capacity of the whole organ are therefore retained. Validation of the metabolic competency of liver slices is routinely performed with an internal standard for which the biotransformation is well defined both in vivo and in vitro. Such a validation procedure will also lead to optimization of culture conditions, aid in judgment of the metabolism competence of the tissue, and increase the power of the prediction of an unknown compound (73) .
Many reports, some of which are reviews utilizing tissue slices as experimental models, indicate that tissue slices are used in drug metabolism mechanistic investigations (73) . Species susceptibility to acetaminophen toxicity in vivo has been demonstrated in vitro (74) . Liver slices of hamster exhibited a dosedependent depletion of glutathione and a greater extent of formation of the toxic metabolite, as determined by glutathione conjugate formation, than rat slices. An 11-fold greater susceptibility to acetaminophen toxicity by the hamster in comparison with the rat was found. Rat liver slices had a greater capacity to form the nontoxic glucuronide and sulfate metabolites than to form the toxic metabolites, while the hamster did not. In another study, cytotoxicity of allyl alcohol and bromobenzene in rat liver slices was inhibited by preincubation of the slices with CYP inhibitors SKF 525 A or pyrazole (75) . The histopathology of the slices paralleled the biochemical changes such as intracellular K + content, LDH leakage, and protein synthesis in the absence of toxicity upon exposure of the slices to CYP inhibitors. These are a few of the many studies utilizing liver slices for metabolic and mechanistic toxicology. MICROSOMES Other in vitro hepatic test systems include the use of microsomes. Microsomes from homogenates and subcellular fractions are certainly useful in many settings and can be recovered from frozen tissues, in contrast to slices and cells (68) . Also, clones of the genes, or at least the cDNAs corresponding to the protein coding regions, for many of the enzymes have been made. Much information can be obtained by expressing an enzyme in a "background cell" system-such as (a) identifying the enzyme's capability to catalyze a particular reaction, (b) identifying a single enzyme's capability to catalyze two reactions thought to be linked, (c) obtaining qualitative insight about the contribution of the individual (iso) enzymes to the activity, and (d) determining if the enzyme forms toxic or mutagenic products (36) . Moreover, there are several expression possibilities for proteins-such as the full-length proteins, shortened versions, modified version of the protein, and the "fusion proteins." There are also several different systems available for expression work-such as transient expression, stable expression in mammalian cells, yeast expression, bacterial expression, and transgenic animals. All of these system's advantages and disadvantages have been reviewed (68) .
ENZYMES Lastly, the use of antibodies is one way to characterize the role of an enzyme in a reaction. Antibodies are generally added to a crude tissue preparation and the extent of inhibition is measured. With some enzymes (e.g. CYP) polyclonal antibodies are usually directly inhibitory; otherwise, precipitation methods can be introduced to help address the issue (68) . Commercial sources of large amounts of antibodies to the enzyme of consideration have been developed to meet the demand that seems to exist.
HEPATIC TOXICITY STUDIES Several in vitro systems have been developed to investigate the hepatic effects of compounds. Intact cellular systems, including hepatocyte and slice cultures, are particularly valuable. These in vitro models closely resemble the biotransformation and functional capacity of in vivo liver, allowing one to predict hepatic effects of compounds in development. Hepatotoxicity is often linked with the biotransformation of the compound; therefore, the in vitro system should reproduce the in vivo biotransformation of compounds to be predictive for in vivo hepatotoxicity. It is becoming apparent that interpatient differences in the levels and catalytic activities of CYP could account for the side effects seen in the therapeutic range of a drug. For example, increasing CYP2E1 levels in chronic alcoholics may predispose these people to acute acetaminophen toxicity. It has also been proposed that the glutathione S-transferases are polymorphic and may contribute to variability in intracellular transport of drugs and activity of detoxification pathways with glutathione. Cellular glutathione pools are important in regulation and maintenance of organelle function and in the maintenance of cellular thiol/disulfide status, of which the liver is the major source of glutathione for the body. Therefore, liver depletion of glutathione would have consequences for other organ toxicities.
Additional studies in our laboratory using various in vitro systems have allowed us to investigate ketoconazole-induced hepatotoxicity. We determined that the rate of disappearance for ketoconazole was almost equal to the rate of N-deacetyl ketoconazole formation, 5.96 and 5.88 mM/h, respectively (76) . Also, the potential bioactivation of N-deacetyl ketoconazole was evaluated by measuring substrate activity of N-deacetyl ketoconazole with purified pig liver FMO and rat liver microsomes. Activity was measured by following N-deacetyl ketoconazole-dependent oxygen uptake polarographically at 37
• C in pyrophosphate buffer, pH 8.8, containing the glucose-6-phosphate NADPH-generating system. The K m values of N-deacetyl ketoconazole were 34.6 and 77.4 mM for the purified FMO and rat microsomal-FMO, respectively. Lastly, N-deacetyl ketoconazole was found to be metabolized by an NADPH-dependent rat liver microsomal monooxygenase at pH 8.8 to two metabolites as determined by HPLC. Heat inactivation of rat liver microsomal-FMO abolished the formation of these metabolites from N-deacetyl ketoconazole. SKF-525A and anti-rat NADPH cytochrome P450 reductase did not inhibit this reaction. These results suggest that deacetylation of ketoconazole yields a major product, N-deacetyl ketoconazole, for further metabolism by microsomal monooxygenases that appear to be FMO related (76) .
One should consider in vitro assays as a potentially valuable guide to choosing the most appropriate animal model for purposes of metabolism. This is an important concern if a particular enzyme might transform a drug into a toxic product. All in vitro work is less than totally adequate in modeling in vivo situations. However, there are ways of properly utilizing in vitro systems to gain insight into problems related to in vivo drug metabolism. All results are only as reliable as the assays. SUMMARY The major contribution of hepatocytes and slices in vitro systems is in defining species susceptibility to the side effects or toxicity of the compound. A goal for these systems is to demonstrate that the data obtained are predictive and can be used reliably in extrapolating from animals to humans for safety assessment. Further validation of the systems for risk assessment will increase the use of data obtained within companies and by regulatory authorities. Such companies could use the data in combination with computer modeling to assess risk.
In vitro cell culture systems will never completely replace animals in toxicity testing; however, if they are used in combination with other human in vitro models, such as liver microsomes, they represent an invaluable tool for performing preclinical studies on the metabolism of drugs and predicting certain drug interactions. They also facilitate the study of mechanisms of toxicity in specific cell types, allowing for rigorous control of the extracellular environment and simplified manipulation of the cells. Culture systems are relatively inexpensive, reproducible, and reliable ways to investigate toxicity at the cellular level. Detailed morphological observations and digitized fluorescence imaging using a variey of fluorescent probes can be performed on cells in culture because of their single cell characteristics (43) .
The in vitro models are being used with great success to accelerate product development, to significantly reduce the numbers of animals required for research, and most importantly, to provide a means for predicting the interaction of drugs and chemicals with human systems long before clinical tests are ethically possible. Ultimately, it is hoped that the application of a suitable battery of mechanistically based in vitro tests may permit certain adverse effects of drugs to be predicted (66) . Hopefully, this trend will continue as in vitro systems are developed and perfected to more accurately mimic other elements of human physiology and function (41) . In the future, in vitro data may change the type and number of in vivo studies performed, resulting in a further reduction in the total number of animals used.
There is a need to put more emphasis on the use of in vitro models of extrahepatic metabolism and for more widespread recognition of the importance of drug biotransformation by enzyme systems other than CYP. Also, it would be valuable if the full functionality of tissue slices and isolated cells could be maintained in culture for longer periods. The relatively poor maintenance of stable biotransformation activities during hepatocyte culture is a major limitation of the current in vitro systems. The maintenance of hepatocyte-specific functions during long-term culture should be explored further, in particular in cocultures and in three-dimensional hepatocyte culture systems (66) . Several aspects must be considered. It is necessary to continue to improve the existing methods of hepatocyte culture for the long-term maintenance of the hepatic phenotype. An extensive comparative analysis between short-term conventional cultures and long-term cultures is needed in terms of drug metabolizing enzyme function and regulation; systems of coculture in which hepatocytes are grown with other liver cells; in vitro perfusion systems mimicking in vivo blood flow could be of interest in toxicity studies; and efforts to develop immortalized human hepatoma cell lines to be used in parallel with normal liver cells should be continued. Isolation and cloning of a hepatoma cell line retaining sufficient hepato-specific features to be used for pharmacological purposes remains to be done (45) .
Despite the obvious usefulness of in vitro methods in this area, regulatory authorities will continue to require data on adsorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics from in vivo studies for the further development of lead compounds in the clinic and for the subsequent licensing of new drugs. Although in vitro information cannot replace in vivo data, it can often provide insight into questions regarding the human metabolism of a drug prior to the initiation of clinical studies. Thus, future research should be directed toward the refinement of existing methodology and the development of new alternatives.
IN VITRO TOXICITY MODELS IN INDUSTRIAL RESEARCH AND DEVELOPMENT
Introduction
Several federal laws require that the public be protected from hazardous commercial products. To protect consumers, the FDA demands that manufacturers extensively test all products for safety prior to their marketing. A drug must pass through a series of tests on animals and humans before it is determined to be safe. Chemical industries (pharmaceutical and chemical manufacturers alike) rely on the science of toxicology to provide information that allows commercial products to be used safely. Toxicologists depend on animal studies to investigate potentially beneficial or harmful effects of drugs and chemicals prior to testing them in humans. Traditionally, the safety assessment process during drug development has been based on screening indiscriminately large numbers of new chemical entities (NCEs) in a battery of animals (naive and disease models) in order to identify new therapeutic candidates with the expectation that one or a few of these NCEs have some competitive advantages over the existing therapeutic agents. That is, they are more efficacious, bioavailable, selective, and safer. This approach is costly, time-consuming, and requires large quantities of test material. Currently, it takes about 10-12 years and over $300 million for a drug to move from laboratory to patient. The need for alternative models in the early phases of the drug discovery process is warranted.
Today, pharmaceutical companies recognize the value in developing in vitro model systems (non-whole-animal models) to assess the safety and efficacy of drugs during development. The quality of information generated from these in vitro model systems, the modest amounts of test compound needed, and the drastic reduction in time, cost, and animals required for any particular study are primary factors that influence the strategy for developing in vitro toxicology tests in industrial settings. During the early stages of drug development, in vitro toxicology contributes to the selection of lead candidates by identifying those compounds with higher probability of success that do not cause adverse effects in a dose range selected to mimic targeted human plasma levels. This contribution focuses on the development of a series of high throughput systems and analytical methodologies to resolve safety issues that may arise during drug selection and development. In vitro data then can be used to improve drug design, to predict class-specific toxicity potential, and more importantly, to facilitate interpretation of animal models of toxicity and their extrapolation to humans for risk assessment purposes. The availability of such in vitro toxicity models in the discovery and development process of pharmaceuticals will reduce time and cost required to develop data needed to initiate Phase I clinical trials in human volunteers.
In Vitro Toxicology Approach to Support Drug Discovery and Development During Preclinical Trials
Generally, in vitro toxicity studies at early stages of drug development are selected based on scientific literature search, computer modeling, structure activity predictions made by toxicologists, and experience with previous safetyrelated issues. Most research projects are designed to provide information of significant value for human health and safety. For example, a proposed preclinical in vitro toxicology scheme for a particular discovery project can be designed using a tier testing approach to screen compounds in a manner coordinated with discovery activities.
Tier I may include (a) a literature review-scientific data are gathered to design and select the most appropriate in vitro and in vivo strategy to help to establish the product alert criteria (e.g. targeted disease, dosing, pharmacological activity and selectivity, clinical end points, marketing, and current competition) and to anticipate safety issues or concerns that may occur during drug development; and (b) the use of computer, physico-chemical, and mathematical models that utilize structure-toxicity relationship analysis for assessing potential toxicological alerts in developmental toxicology, rat oral LD 50 , Ames mutagenicity, and rodent carcinogenicity. These models can flag some possibly toxic chemicals by comparing their characteristics to those known to be toxic. Many NCEs can be assessed (20/week) and potential candidates that show positive results will require more specific studies to rule out or verify toxic potential.
Tier II may include in vitro assay systems for assessing potential genotoxicity. Short-term tests are selected to detect agents operating through genotoxic mechanisms. These include the Ames test and the in vitro micronucleus assay. The Ames test, a salmonella point mutation assay that utilizes five tester strains, is routinely used in the screening of drugs for potential mutagenic activity. Homogenized rat liver (S9) is added to the test system to detect promutagens. The basis of the Ames test is that the salmonella bacteria cannot reproduce in a certain type of growth medium unless the bacteria have undergone a mutation. The microAmes test (abbreviated Ames test) is a high throughput screen test that uses two tester strains and requires a small amount of test article (approximately 2 mg of compound). This assay has been shown to be a sensitive, accurate, and rapid indicator of mutagenic activity of a broad range of chemical classes. The in vitro micronucleus assay, on the other hand, assesses the effect of a compound on the induction of chromosomal breakage or clastogenesis. This assay evaluates the induction of micronuclei, which is the product of chromosomal breakage using Chinese hamster ovary (CHO) cells. Since micronuclei occur in the cytoplasm following cell division, induced micronuclei can be definitively analyzed in binucleated cells. Twenty-four hours following NCE exposure, which can be with or without metabolic activation by S9, the cells are fixed, stained, and analyzed. End points analyzed are the replication kinetics and the percentage of binucleate cells with micronuclei. This high throughput assay is also compound efficient (approximately 3 mg is required) and, in conjunction with the microAmes test, can be completed in a one-week turnaround. These early genetic toxicity testings help distinguish classes of chemistry, predict class toxicity potential, and identify compounds for more detailed testings.
Tier III is generally conducted on test chemicals considered strong candidates for the in vivo efficacy testing. Tier III may focus on the potential of the NCEs to interfere with specific tissue and/or host cell function. For example, targeting specific enzymes, genes, proteins, or receptors associated with either a disease or with the control of a critical physiological process may be investigated. Examples of in vitro toxicity models included in Tier III are cell culture systems (primary or established cell lines), tissue slices, isolated perfused tissues, subcellular fractions, purified enzymes, and reporter gene constructs. Cytotoxicity assays, enzyme induction, DNA synthesis, protein synthesis perturbations, cell cycle analysis, and apoptosis can be measured as end points. Many of these end points can be examined using primary rat and/or human hepatocytes. Hepatocytes are chosen because the liver is the most common site for toxicity and tumorigenic responses in vivo and because of their high metabolic and synthetic capacity. This tier requires less than 30 mg of chemical, and the turnaround time is targeted within a two-week period.
Tier IV may involve customized in vitro assays to investigate unique toxic action (e.g. the use of primary hepatocyte cultures to determine toxicity by the formation of reactive intermediate metabolites), exaggerated pharmacology responses (e.g. the use of isolated bile canaliculi membranes to investigate cholestasis caused by long-term treatment with NCE which result in toxicity), or specialized tests as part of in vivo discovery studies (e.g. monitoring complement activity as potential nonselective mammalian target of antiviral serine-protease inhibitor compounds). Moreover, because of the potential of NCEs to interact with different tissues or selective systemic targets, early shortterm in vivo testings are recommended. The assessment of clinical chemistry, pharmacokinetics, and anatomic and clinical pathology parameters can be included in this tier. The turnaround time for the results from these toxicity testings are generally targeted within a two-week period.
The information obtained from these early toxicological screens will allow one to rank lead NCEs for toxic effects in vivo. The use of in vitro toxicity models in the early stages of drug development will reduce time, cost, and animal use and will help in the selection of NCEs with the lowest potential for preclinical and clinical toxicity and with the highest probability for marketing success.
Primary Adult Rat Hepatocytes as Predictive In Vitro Model for Cytotoxicity and Carcinogenicity
Cultured hepatocytes (rodent or human origin) represent a useful tool for studying hepatotoxicity, drug metabolism, liver enzyme induction, and carcinogenicity (77) (78) (79) (80) (81) (82) (83) . The most common in vitro systems used to study the metabolism and hepatotoxicity of xenobiotics in the liver are primary monolayers of rat (77) (78) (79) and human hepatocytes (80, 81) , precision-cut liver slices (82) , and immortalized cell lines (83) . Microsomes and purified enzyme systems are also routinely used for examining hepatic metabolism of drugs and chemicals (84) . Although the use of microsomes and purified enzymes have significant advantages and applications (e.g. samples are easily prepared, enzyme induction is quickly determined, specific isozyme(s) responsible for drug metabolism can be identified, and most importantly, the sample can be stored for long periods of time without loss of xenobiotic metabolism activity), the use of intact cells (e.g. primary cultures of rat hepatocytes) is the in vitro system of choice to study metabolism of xenobiotics and to predict drug-induced hepatotoxicity in vivo. Because both Phase I and II metabolic pathways are coupled in the intact cell preparation, it makes this system more similar to the in vivo situation.
Generally, under conventional culture conditions, primary monolayers of rat hepatocytes fail to preserve or restore differentiated specific liver functions and responses characteristic of the intact target tissue and maintain the functional expression of genes measured in vivo (78) . Recent evidence suggests that primary rat hepatocytes cultured under conditions that restore the normal morphology (e.g. cell polarity) and liver gene expression (e.g. albumin and liver metabolizing enzymes) can respond to xenobiotics at levels comparable with those achieved in vivo (85) (86) (87) (88) (89) . Examples of these culture conditions include the use of an extracellular matrix (e.g. sandwiching the hepatocytes between collagen and an overlay of Matrigel ® ) (79, (85) (86) (87) , chemically defined culture conditions (e.g. the use of low concentrations of insulin and dexamethasone in a serum-free amino acid-rich culture medium) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) , and coculture hepatocytes with cells of nonhepatic origin (e.g. kidney epithelial cells) (47, 90) . The in vitro induction of hepatic metabolizing enzymes (e.g. cytochrome P450 and Phase II conjugating enzymes) by drugs and chemicals are markedly enhanced by the following conditions: (a) high percentage viability of isolated parenchymal cells (>94%), (b) adding insulin (1 µM) and hydrocortisone (0.1 µM) to the serum-free culture medium, (c) using ECM such as Matrigel ® (overlay or sandwich); and (d) adding the chemicals at 24 and 48 h after plating. It has been reported that continuous 48-h exposure to liver enzyme inducer agents results in the induction of enzyme expression at both mRNA and protein levels (92) . Rat hepatocytes cultured under these conditions are far superior to those previously available. This cell culture condition retards mRNA degradation and facilitates high rates of protein synthesis. Hepatotoxicity and metabolism studies are improved by maintenance of differentiated state of the cell. For safety assessment, the metabolism of NCEs in a variety of animal species is important in determining exposures that aid in the development process.
The identification and characterization of carcinogens (primary acting or secondary acting agents) have represented a significant challenge to toxicologists. In vitro models to investigate the molecular mechanisms of hepatocarcinogenicity induced by xenobiotics with suitable sensitivity and specificity have been particularly elusive. A major area of investigation in pharmaceuticals is to study the effects of carcinogens on the gene expression of hepatic metabolizing enzymes and identify early detectable and sensitive molecular markers linked with chemicals having mechanism-based carcinogenic potential. The induction of cytochrome P450 (CYP450) isoforms (e.g. CYP1A, CYP2B, CYP3A, and CYP4A isozymes) and Phase II conjugating enzymes [e.g. uridine diphosphateglucuronyl transferase (UDPGT), glutathione-S-transferase (GST), and sulfotransferase (ST)] has been associated with drug-drug interactions in humans, and increases in liver weight, proliferation of the endoplasmic reticulum, and nongenotoxic liver carcinogenicity and tumorigenicity in rodents (93) (94) (95) .
Rat hepatocytes cultured on Matrigel ® in chemically defined media are useful systems for identifying and characterizing genes that are differentially expressed in response to exposure of carcinogens, especially compounds such as phenobarbital, DDT, estradiol, and diethylstilbestrol, which have been reported to exert carcinogenic effects through an epigenetic mechanism (96, 97) . In addition, hepatocytes cultured under these conditions respond to prototypical metabolizing enzyme inducers such as 3-methylcholanthrene, hydrocortisone, and clofibrate in a similar fashion to rats exposed to these or comparable prototypical liver enzyme inducers (92) .
Several methodologies have been coupled with rat hepatocytes to monitor the regulation of metabolic liver enzymes linked with carcinogenicity following exposure of xenobiotics. The past decade has brought about several advances in molecular biology and the cloning and sequencing of many liver drug-metabolizing genes from rodents and humans (98) (99) (100) (101) . The expression of these CYP450 enzymes can be measured efficiently and selectively at the mRNA level. Using reverse transcriptase polymerase chain reaction (RT-PCR), a profile of gene expression can be measured easily in any tissue. RT-PCR involves primer-mediated enzymatic in vitro amplification of specific target DNA sequences (98, 99, 101) . Today, RT-PCR has become an essential molecular biology tool in investigative toxicology for providing an in-depth understanding of the molecular basis of chemically induced toxicity and carcinogenicity (99) (100) (101) . RT-PCR is probably the most sensitive means to quantitate gene expression, where RNA (cDNA) sequences can be amplified from a single cell (98) .
In situ hybridization (ISH) has also been used for detection and localization of gene expression. Basically, cell-bound RNA is visualized by microscopy after sequences hybridize with labeled probes of complementary sequence. ISH provides data on individual cells rather than an average of total cell population. ISH coupled with PCR allows more sensitive detection of low copy numbers of specific mRNA sequence in a cell preparation (102) .
Recently, two novel techniques have been developed to study the overall expression profiles of genes in cells and tissues; these are known as differential display (RAPD) and cDNA AFLP (amplified fragment length polymorphism) imaging (103) (104) (105) . Both techniques rely on the random PCR amplification of DNA fragments to be displayed through several complementary DNA fingerprints. Several reports have suggested that AFLP imaging is more precise, reproducible, and reliable than RAPD, based on the fact that one can mathematically calculate how many fingerprints are needed to cover any complex RNA sample; thus the principle of selective restriction fragment amplification is precisely understood and controlled (103) (104) (105) .
The coupling of rat hepatocytes cultured on Matrigel ® with enzyme mRNA expression analysis by using PCR techniques has proven to be a valuable and important in vitro toxicological approach to accurately assess chemically induced changes in expression of liver CYP450 and Phase II conjugating enzymes and to provide new insights into the molecular basis of toxicity and carcinogenicity.
Another short-term in vitro test to investigate carcinogens using hepatocytes is the DNA repair assay (96, 97, 106) . This assay utilizes the metabolic capability of the liver and the specificity of the DNA repair as an indicator of DNA damage. The quantitation of incorporated radioactive thymidine is used as an indicator of induced unscheduled DNA synthesis. The interaction with DNA, which is recognized as damaged and repaired by excision repair mechanisms, results in an increase in unscheduled DNA synthesis. The autoradiography measurement of DNA repairs allows the cells undergoing replicative DNA synthesis to be distinguished from those in repair. This assay distinguishes genotoxic from nongenotoxic chemicals of a wide variety of structural classes and is sometimes included as a part of the battery tests in the Tier II testing strategy to screen compounds as potential carcinogens. The DNA repair assay has proven to be sensitive and reliable with agents that require metabolic activation, including some not readily detected by other systems (96) .
In addition to primary hepatocytes, selective cell lines (e.g. hepatomas and Syrian hamster and CHO cells) are also commonly used as a model for identifying potentially genotoxic or epigenetic NCEs. For example, the Syrian hamster embryo (SHE) cell transformation assay at pH 6.7 reportedly provides both the sensitivity and the specificity needed to identify and assess potential rodent carcinogens and noncarcinogens and elucidates the mechanism of chemical carcinogens (107, 108) . This assay utilizes frozen primary cell cultures from 13-day-old SHEs. Irradiated cells (feeder) are seeded in 60-mm dishes for 24 h followed by seeding of nonirradiated SHE (target) cells. After 24 h in culture, cells are treated with NCEs for 24 h and incubated in a 10% CO 2 environment at 37
• C for 7 days. Cells are then fixed and stained with Giemsa, and the colonies are scored under low magnification for morphological transformation. This assay has been reported to have an overall concordance of 85%, a sensitivity of 87%, and a specificity of 83%, which is consistent with a larger historical database of over 200 chemicals (108) .
Moreover, the induction of prolonged cell proliferation has also been suggested as a mechanism of nongenotoxic carcinogens. The use of CHO cells and the 5-bromo-2-deoxyuridine (BrdUrd) labeling probe has shown to be especially useful in assessing chemically induced cell proliferation (96, 97, 109) .
CONCLUSIONS
In vitro model systems have made significant contributions to our understanding of the mechanisms of toxicity and carcinogenicity, metabolism of drugs and chemicals, and the species differences in expression of toxicity. Furthermore, they are an indispensable resource for investigative toxicology and play a key role in identifying potentially toxic compounds at early stages of drug development for eventual human health risk assessment.
